Lazcluze savings card: $0 a fill with commercial insurance

How to pay the least

Ask for the cash price

Lazcluze

We didn’t find one.

Ask your pharmacy for Lazcluze’s cash price, and one or two other pharmacies too.
Lazcluze’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL). Or call 1-833-742-0791.

See if you qualify

Compare every option

Brand nameLazcluze

Authorized genericlazertinib

Regular genericlazertinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Lazcluze?

The original

–

Brand nameThe maker’s card

J&J withMe Savings Program

Savings card from Johnson & Johnson

No insuranceNeeds insuranceNo cash price listed.

Insurance $0 a fill

Or call 1-833-742-0791.

In the maker’s words

“Eligible patients pay $0 for each RYBREVANT FASPRO™ or RYBREVANT® dose and LAZCLUZE® prescription fill when LAZCLUZE® is used in combination with either of these medicines.”

From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Lazcluze itself, from the same company, sold without the brand name, and usually for less. For now Lazcluze is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Lung cancer (NSCLC) with certain EGFR mutations

What the FDA label says

LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

Source: the FDA label for Lazcluze (Janssen Biotech, Inc.), May 5, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/lazcluze/